as 11-15-2024 4:00pm EST
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.
Founded: | 2017 | Country: | United States |
Employees: | N/A | City: | NEWARK |
Market Cap: | 48.4M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 26.3K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.45 | EPS Growth: | N/A |
52 Week Low/High: | $1.29 - $2.50 | Next Earning Date: | 12-12-2024 |
Revenue: | $637,000 | Revenue Growth: | 128.32% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
RFL Breaking Stock News: Dive into RFL Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
GlobeNewswire
3 months ago
Simply Wall St.
5 months ago
GlobeNewswire
5 months ago
GuruFocus.com
5 months ago
Energy Global
5 months ago
USA TODAY
5 months ago
Business Wire
5 months ago
The information presented on this page, "RFL Rafael Holdings Inc. Class B - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.